About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Pfizer Acquires Amplyx Pharmaceuticals
Opportunity to advance Pfizer s expertise and deep heritage in infectious disease
NEW YORK Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx s lead compound, Fosmanogepix (APX001), is a novel investigational asset
Pfizer Acquires Amplyx Pharmaceuticals
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Real-World Evidence Supports Effectiveness of First-line IBRANCE® Combination Therapy in HR+, HER2- Metastatic Breast Cancer
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Big Pharma.
After the Massachusetts governor suggested last week that people should question why vaccine manufacturers had “not delivered” in recent months on the promised levels of doses, the Pharmaceutical Research and Manufacturers of America (PhRMA) accused Baker of “attacking the very people who are doing everything they can to end this pandemic.”
Related Links
“Biopharmaceutical researchers have worked tirelessly over the last year to research and develop treatments and vaccines for COVID-19,” Priscilla VanderVeer, the vice president of public affairs for PhRMA, said in a statement, which was first reported by the State House News Service. Advertisement
“Instead of recognizing the tremendous progress that has been made, Governor Baker is attacking the very people who are doing everything they can to end this pandemic – many of whom call Massachusetts home,” VanderVeer said. “Rather than playing a blame game, Gov. Baker should take a lesson from his c
Biden vaccine victories build on Trump team s work
Dan Diamond and Isaac Stanley-Becker, The Washington Post
March 11, 2021
FacebookTwitterEmail
President Joe Biden listens Wednesday as leaders from Johnson & Johnson and Merck spoke during an event at the White House.Washington Post photo by Jabin Botsford
WASHINGTON - President Joe Biden beckoned leaders of two of the world s largest pharmaceutical companies to the White House on Wednesday and credited his administration for the nearly unprecedented collaboration between the longtime rivals, Merck and Johnson & Johnson, now jointly producing acoronavirus vaccine.
But the breakthrough touted by Biden was first conceived by Trump officials last year, culminating in a Jan. 4 conference call arranged between Merck and Johnson & Johnson s senior leaders, said four Trump administration officials with knowledge of the efforts.